Pandemic Darlings The pandemic economy, in original documents
Home Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 06/15/2020Search ⌕

Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 06/15/2020

Summary

A Form 4 for Henry Ji, a director and officer of Sorrento Therapeutics, Inc. [SRNE], whose remarks list the title President, CEO and Chairman of the Board of Directors. It reports stock options acquired on June 15, 2020 covering 1,500,000 shares of common stock at $4.89, expiring 06/15/2030. According to the footnote, 1/4th of the shares vests on June 15, 2021 and 1/48th after each one month period of service thereafter, subject to continued service. No common stock transactions are listed. The form is signed /s/ Henry Ji, Ph.D. on 06/15/2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Form 4: Sorrento Therapeutics, Inc. (SRNE), Ji Henry, transaction 06/15/2020.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-4-filed2020-06-15-0000850261-20-000040-0136281aaf/, SHA-256 daa7805fb78bccc7932f4d431c62ee3e9256bb8351ee75876d775b3687f385c8.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Ji Henry (Last) (First) (Middle) C/O SORRENTO THERAPEUTICS, INC. 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | Ji Henry | (Last) | (First) | (Middle) | C/O SORRENTO THERAPEUTICS, INC. | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [ SRNE ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) See Remarks | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | See Remarks
3. Date of Earliest Transaction
 (Month/Day/Year) 06/15/2020
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Options | $ 4.89 | 06/15/2020 | A | 1,500,000 | (1) | 06/15/2030 | Common Stock | 1,500,000 | $ 0 | 1,500,000 | D
Explanation of Responses:
1. 1/4th of the original number of shares subject to the option shall vest on June 15, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month period of service after June 15, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Remarks:
President, CEO and Chairman of the Board of Directors
/s/ Henry Ji, Ph.D. | 06/15/2020
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_SRNE_4_filed2020-06-15_0000850261-20-000040.xml
Size
15,705 bytes
SHA-256
daa7805fb78bccc7932f4d431c62ee3e9256bb8351ee75876d775b3687f385c8
Our copy
SEC_SRNE_4_filed2020-06-15_0000850261-20-000040.xml
Original
www.sec.gov
Back to top